21.02.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
DGAP-News: MorphoSys AG / Key word(s): Study
MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical
Study with Lanthipeptide MOR107
21.02.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, February 21, 2017
MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical
Study with Lanthipeptide MOR107
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today that its fully owned subsidiary Lanthio Pharma B.V.,
Groningen, Netherlands, has initiated a phase 1 clinical study with MOR107.
MOR107, a selective agonist of the angiotensin II receptor type 2, is a
lanthipeptide based on Lanthio Pharma's proprietary technology platform and
the first lanthipeptide in MorphoSys's clinical pipeline.
The goal of the trial is to evaluate safety, tolerability, pharmacokinetics
and pharmacodynamics of subcutaneously administered single ascending doses
(SAD) of MOR107 in healthy male volunteers. The randomized, double-blind,
placebo-controlled phase 1 study will be conducted in a single center in
the United Kingdom and will enroll 80-110 subjects.
Topline results of the study are expected in the second half of 2017.
"We are delighted to see the first lanthipeptide program from our Dutch
subsidiary Lanthio Pharma entering clinical development. MOR107 is the
sixth program from MorphoSys's proprietary portfolio in clinical trials.
The start of this innovative investigational program reflects the growing
value and maturity of our development pipeline", commented Dr. Marlies
Sproll, Chief Scientific Officer of MorphoSys AG.
"We are excited that with MOR107, the first compound from our technology
platform has started clinical development", said Dr. Axel Mescheder, Chief
Medical Officer of Lanthio Pharma B.V. "Lanthipeptides are an interesting
class of peptide molecules that have been engineered with the intention to
further enhance stability and selectivity of this compound class."
About Lanthio Pharma and MOR107
Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG since 2015,
is a Dutch biopharmaceutical company committed to developing and
commercializing therapeutic peptides to activate difficult to target
receptors (e.g. GPCRs). With its proprietary technology, Lanthio Pharma is
generating lanthipeptides, a new class of cyclical peptide molecules which
have been engineered with the intention to achieve enhanced stability and
selectivity. Lanthio Pharma is focused on the protective arm of the Renin-
Angiotensin System (RAS). Lanthio Pharma has currently two programs
targeting the two key receptors in this pathway. The lead product is MOR107
(formerly LP2-3), a selective AT2 receptor agonist. MOR107 is currently
investigated in a "first-in-human" clinical study in healthy volunteers.
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
21.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
545861 21.02.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR